Related Experiment Video
Updated: Jun 4, 2025
05:25
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
1.4K
Antibodies to watch in 2025
Silvia Crescioli1, Hélène Kaplon2, Lin Wang3
1Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, USA.
Mabs
|December 23, 2024
Summary
Antibody therapeutics saw 21 new approvals in 2024, with 30 more under review. Key trends in bispecific antibodies and antibody-drug conjugates (ADCs) are shaping the future of cancer treatment.
Area of Science:
- Biopharmaceutical Development
- Oncology Therapeutics
- Immunotherapy
Background:
- Over 200 antibody therapeutics are approved, with nearly 1,400 candidates in clinical trials.
- Antibody therapeutics represent a significant global biopharmaceutical enterprise.
Purpose of the Study:
- To review key antibody therapeutic development events in 2024.
- To forecast late-stage clinical pipeline events for 2025.
- To analyze trends in antibody formats like bispecifics and antibody-drug conjugates (ADCs).
Main Methods:
- Analysis of regulatory approvals and marketing application reviews for antibody therapeutics.
- Review of late-stage pipeline candidates with anticipated 2025 marketing applications.
- Examination of clinical-phase transition and global approval success rates for different antibody formats.
Main Results:
- 21 antibody therapeutics received first approval in 2024, including bispecifics and ADCs.
- 30 antibody therapeutics were under regulatory review as of December 9, 2024.
- 18 late-stage pipeline candidates may submit marketing applications by end of 2025.
Conclusions:
- Bispecific antibodies and ADCs are key formats driving innovation in antibody therapeutics.
- Continued growth and diversification of the antibody therapeutic pipeline are expected.
- Analysis of approval trends provides insights into the evolving landscape of antibody-based medicines.
Related Concept Videos
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
01:25Antibody Structure and Classes
805
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
805
00:42Cross-reactivity
31.0K
Overview
31.0K
01:10Antibody Structure
59.0K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.0K
01:26Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K